| Code | CSB-RA024404MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to CEL-383, designed for research targeting TREM1 (Triggering Receptor Expressed on Myeloid cells 1). TREM1 is a cell surface receptor belonging to the immunoglobulin superfamily that amplifies inflammatory responses by synergizing with pattern recognition receptors such as TLRs. Upon ligand binding, TREM1 activates intracellular signaling pathways that enhance the production of pro-inflammatory cytokines and chemokines in myeloid cells, including neutrophils, monocytes, and macrophages. Dysregulated TREM1 signaling has been implicated in sepsis, acute respiratory distress syndrome, inflammatory bowel disease, and various autoimmune conditions, making it a significant therapeutic target for modulating excessive inflammation.
The reference antibody CEL-383 has been utilized in preclinical studies investigating TREM1's role in inflammatory pathways and immune responses. This biosimilar provides researchers with a reliable tool for exploring TREM1 biology, studying innate immune mechanisms, and evaluating potential therapeutic interventions in inflammation-related disorders. It supports diverse experimental approaches in immunology and inflammatory disease research.
There are currently no reviews for this product.